ArticleSmall science2025
Fluorinated Zirconium-Based Metal-Organic Frameworks as Novel Sorbents to Improve the Efficacy of Hemodialysis Treatment.
Article in Small science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Use of the MOF NU-1000 as a Drug Delivery System for the Antineoplastic Drug Mitoxantrone.International journal of molecular sciences · 2026Article
- Indoxyl sulfate in the gut-kidney axis: from diet-microbiome interactions to renal injury and targeted therapies.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
People with end-stage chronic kidney disease (CKD) require routine dialysis treatments to remove uremic toxins from the blood in order to minimize toxic symptoms. However, some hydrophobic toxins cannot be effectively removed using conventional hemodialysis techniques, especially when they are bound to plasma proteins. This work reports the first experimental evidence addressing this issue through the incorporation of perfluoroligands into a zirconium-based metal-organic framework, taking advantage of the favorable interactions between fluorine atoms and albumin proteins. The as-designed fluorinated NU-1000 particles (NU@F) demonstrate their capability to remove not only free hydrophobic uremic toxins, specifically p-cresyl sulfate (pCS) and indoxyl sulfate (IS), but also a large fraction of those bound to human serum albumin, notably without causing significant hypoalbuminemia. The NU@F particles incorporated into a cartridge also exhibit good performance under dynamic flow conditions, mimicking the real scenario of hemodialysis. Finally, the NU@F dialysis system is tested in a pooled sample from CKD patients, confirming the actual application potential of the developed prototype system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.